Payment overview · 2025
General Payments
$321.78
13 reported records · 7 companies
Healthcare provider profile · identity verified
Hayeon Park, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SUWANEE, GA · NPI 1376076950
Verified facts
What the public records show
CMS Open Payments records show Hayeon Park, NP-C received $321.78 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.43 | 46.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.05 | 12.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.34 | 11.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.10 | 9.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.02 | 9.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.46 | 6.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.38 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.78 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.05 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 117 |
| Lidocaine | Lidocaine | 179 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 63 |
| Vascepa | Icosapent Ethyl | 147 | 46 |
| Losartan Potassium | Losartan Potassium | 121 | 48 |
| Metformin Hcl | Metformin Hcl | 119 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 42 |
| Famotidine | Famotidine | 93 | 50 |
| Donepezil Hcl | Donepezil Hcl | 92 | 32 |
| Celecoxib | Celecoxib | 89 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 89 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 50 |
| Metformin Hcl Er | Metformin Hcl | 68 | 32 |
| Creon | Lipase/Protease/Amylase | 67 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 18 |
| Jardiance | Empagliflozin | 62 | 18 |
| Lisinopril | Lisinopril | 58 | 22 |
| Omeprazole | Omeprazole | 56 | 31 |
| Alendronate Sodium | Alendronate Sodium | 52 | 24 |
| Gabapentin | Gabapentin | 51 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 34 |
| Montelukast Sodium | Montelukast Sodium | 48 | 24 |
| Prolia | Denosumab | 48 | 32 |
| Simvastatin | Simvastatin | 44 | 14 |
| Azithromycin | Azithromycin | 42 | 42 |
| Finasteride | Finasteride | 42 | 13 |
| Meloxicam | Meloxicam | 40 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Azelastine Hcl | Azelastine Hcl | 31 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | 11 |
| Linzess | Linaclotide | 28 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 26 |
| Valacyclovir | Valacyclovir Hcl | 25 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 24 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | 11 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 12 |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Atenolol | Atenolol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Ztlido | Lidocaine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.78 · 13 records | Novo Nordisk Inc | ABRYSVO, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ETERNA, GARDASIL 9, MOUNJARO, Ozempic, PREVNAR 20, Wegovy, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error